Is Adial Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: ADIL) stock is to Strong Buy ADIL stock.
Out of 1 analyst, 1 (100%) are recommending ADIL as a Strong Buy, 0 (0%) are recommending ADIL as a Buy, 0 (0%) are recommending ADIL as a Hold, 0 (0%) are recommending ADIL as a Sell, and 0 (0%) are recommending ADIL as a Strong Sell.
What is ADIL's earnings growth forecast for 2025-2025?
(NASDAQ: ADIL) Adial Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.
Adial Pharmaceuticals's earnings in 2025 is -$13,197,451.
In 2025, ADIL is forecast to generate -$12,886,192 in earnings, with the lowest earnings forecast at -$17,751,388 and the highest earnings forecast at -$8,020,997.
What is ADIL's forecast return on equity (ROE) for 2025-2028?
(NASDAQ: ADIL) forecast ROE is N/A, which is considered weak.
What is ADIL's Price Target?
According to 1 Wall Street analyst that have issued a 1 year ADIL price target, the average ADIL price target is $8.00, with the highest ADIL stock price forecast at $8.00 and the lowest ADIL stock price forecast at $8.00.
The Wall Street analyst predicted that Adial Pharmaceuticals's share price could reach $8.00 by Nov 14, 2025. The average Adial Pharmaceuticals stock price prediction forecasts a potential upside of 1,059.42% from the current ADIL share price of $0.69.
What is ADIL's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: ADIL) Adial Pharmaceuticals's current Earnings Per Share (EPS) is -$2.72. In 2025, ADIL's EPS is forecast to hit -$1.96 (min: -$2.70, max: -$1.22).
What is ADIL's forecast return on assets (ROA) for 2025-2028?
(NASDAQ: ADIL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.65%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.